These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6863321)

  • 1. The reactogenicity and immunogenicity of the Urabe Am 9 live mumps vaccine and persistence of vaccine induced antibodies in healthy young children.
    Ehrengut W; Georges AM; André FE
    J Biol Stand; 1983 Apr; 11(2):105-13. PubMed ID: 6863321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunizing effect and reactogenicity of two live attenuated mumps virus vaccines in Swedish schoolchildren.
    Christenson B; Heller L; Böttiger M
    J Biol Stand; 1983 Oct; 11(4):323-31. PubMed ID: 6643511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells.
    Glück R; Hoskins JM; Wegmann A; Just M; Germanier R
    Dev Biol Stand; 1986; 65():29-35. PubMed ID: 3556774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain.
    Vesikari T; André FE; Simoen E; Florent G; Ala-Laurila EL; Heikkinen A; Kuusinen H; Terho A
    Acta Paediatr Scand; 1983 Jan; 72(1):37-40. PubMed ID: 6344550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children.
    Vesikari T; André FE; Simoen E; Florent G; Ala-Laurila EL; Heikkinen A; Kuusinen H; Terho A
    Acta Paediatr Scand; 1983 Jan; 72(1):41-6. PubMed ID: 6344551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Testing for the safety, reactogenicity and antigenic properties of a live thermostable mumps vaccine made from the Leningrad-3 strain].
    Iuminova HV; Liashenko VA; Krasnova VP; Krivenkova VN; Goliazhenkova MIu; Unanov SS
    Vopr Virusol; 1991; 36(4):310-2. PubMed ID: 1796587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Virus strain specific serum neutralizing antibodies in children and adolescents immunized with a Russian mumps vaccine].
    Otrashevskaia EV; Krasil'nikov IV; Ignat'ev GM
    Vopr Virusol; 2010; 55(6):15-9. PubMed ID: 21381334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
    Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
    Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
    Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
    Davidkin I; Valle M; Julkunen I
    Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of school children with live mumps virus vaccine.
    Furesz J; Nagler FP
    Can Med Assoc J; 1970 May; 102(11):1153-5. PubMed ID: 5420994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inoculation properties of live combined vaccine against measles and mumps].
    Vasil'eva GA; Slatin EA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):70-5. PubMed ID: 6880482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of mumps in preschool institutions using a live mumps vaccine made from strain L-3].
    Garaseferian MG; Bolotovskiĭ VM; Shatrova LP; Titova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Apr; (4):39-42. PubMed ID: 2970740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of a combined live mumps-measles vaccine].
    Unanov SS; Korzh IuN; Dorofeev VM; Iuminova NV; Myshliaeva LA
    Vopr Virusol; 1987; 32(6):715-8. PubMed ID: 3445589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of one-dose mumps-containing vaccine effectiveness on wild-type genotype F mumps viruses circulating in mainland China.
    Cui A; Zhu Z; Mao N; Si Y; Ma Y; Hu Y; Deng X; Wang L; Zeng L; Zhang Y; Xu W
    Vaccine; 2018 Sep; 36(38):5725-5731. PubMed ID: 30122648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.